Brookdale Senior Living Inc. BKD recently announced that its June 2024 weighted average occupancy grew 140 basis points (bps) from the year-ago level to 78.2%, thanks to greater than pre-pandemic average move-in volumes and lower move-outs. The weighted average occupancy for the second quarter increased 160 bps year over year, reaching 78.1%. This marks a great start to the year, along with a similar 160 bps year-over-year increase to 77.9% in the first quarter. This positive trend is expected to persist, driven by the projected growth in the senior population, which will likely enhance the company's overall performance. The company is expected to have witnessed 32 straight months of year-over-year increases in weighted average occupancy. This suggests that it is witnessing continuous growth in occupancy rates, which is expected to result in higher resident fee revenues. In the first quarter of 2024, resident fee revenues increased 4.3% year over year to $744.2 million, while RevPAR (revenue per available unit) and Adjusted EBITDA grew 6.7% and 10.1% year over year, respectively. Per BKD’s earlier guidance, second-quarter 2024 RevPAR was expected to grow 6.25-6.75% year over year, and adjusted EBITDA was projected to be in the $93-$98 million range. The increases in RevPAR and occupancy likely contributed positively to its results. The Zacks Consensus Estimate for the second-quarter 2024 bottom line indicates a 13.3% improvement from the prior year's figure. It has witnessed no movement in the estimate in the past week. It's worth noting that BKD has beaten earnings estimates in two of the last four quarters and missed on the other occasions. Price Performance Brookdale Senior shares have jumped 68.3% in the past year, outperforming the industry average of 43.1%. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Stocks to Consider Brookdale Senior currently carries a Zacks Rank #3 (Hold). Investors interested in the broader Medical space may look at some better-ranked players like Altimmune, Inc. ALT, Elevance Health, Inc. ELV and Annovis Bio, Inc. ANVS, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Altimmune’s 2024 bottom line suggests a 6.3% year-over-year improvement. ALT beat earnings estimates in each of the past four quarters, with an average surprise of 10.3%. The consensus mark for its current-year revenues is pegged at $250 million, indicating a massive year-over-year increase. The Zacks Consensus Estimate for Elevance Health’s current-year earnings implies a 12.4% increase from the year-ago reported figure. ELV beat earnings estimates in each of the last four quarters, with an average surprise of 2.8%. The consensus mark for its current-year revenues is pegged at $171.8 billion, which indicates a 0.9% year-over-year increase. The Zacks Consensus Estimate for Annovis Bio’s current-year earnings suggests a 50% year-over-year improvement. It has witnessed two upward estimate revisions over the past 60 days against no movement in the opposite direction. ANVS beat earnings estimates in three of the past four quarters and missed once. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Altimmune, Inc. (ALT):Free Stock Analysis Report Brookdale Senior Living Inc. (BKD):Free Stock Analysis Report Annovis Bio, Inc. (ANVS):Free Stock Analysis Report Elevance Health, Inc. (ELV):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Brookdale Senior (BKD) Q2 Occupancy Jumps, Growth Trend Persists
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...